P1173: EARLY ADMINISTRATION OF POLATUZUMAB VEDOTIN AS BRIDGING CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IS AN EFFECTIVE STRATEGY TO IMPROVE SURVIVAL IN PATIENTS WITH R/R B-CELL LYMPHOMA

• Fan Yang,
• Rui Liu,
• Zhonghua Fu,
• Teng Xu,
• Peihao Zheng,
• Shaomei Feng,
• Yuelu Guo,
• Lixia MA,
• Hui Shi,
• Biping Deng,
• Xiaoyan Ke,
• Kai Hu

Affiliations

Fan Yang

1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China

Rui Liu

1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China

Zhonghua Fu

1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China

Teng Xu

1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China

Peihao Zheng

1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China

Shaomei Feng

1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China

Yuelu Guo

1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China

Lixia MA

1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China

Hui Shi

1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China

Biping Deng

1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China

Xiaoyan Ke

1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China

Kai Hu

1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China